Tereza Popkova

Tereza Popkova

Auto-generated profile, based on publicly available information

Tereza Popkova

Department of Haematooncology University Hospital Ostrava Ostrava Czech Republic

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
TJTomas Jelinek
Tomas Jelinek
RBRenata Bezdekova
Renata Bezdekova
DZDavid Zihala
David Zihala
TSTereza Sevcikova
Tereza Sevcikova
ASAnjana Anilkumar Sithara
Anjana Anilkumar Sithara
RHRoman Hajek
Roman Hajek
PURPOSE: Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to ≥ 5%. We hypothesized that primary PCL is not a separate clinical entity, but rather that it represents ultra-high-risk multiple myeloma (MM) characterized by elevated CTC levels. METHODS: We assessed the levels of CTCs by multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM to establish a cutoff for CTCs that identifies the patients with ultra-high-risk PCL-like MM. We tested the cutoff on 185 transplant-eligible patients with MM and further validated on an independent cohort of 280 transplant-ineligible patients treated in the GEM-CLARIDEX trial. The largest published real-world cohort of patients with primary PCL was used for comparison of survival. Finally, we challenged the current 5% threshold for primary PCL diagnosis. RESULTS: Newly diagnosed transplant-ineligible patients with MM with 2%-20% CTCs had significantly shorter progression-free survival (3.1 v 15.6 months; P < .001) and overall survival (14.6 v 33.6 months; P = .023) than patients with < 2%. The 2% cutoff proved to be applicable also in transplant-eligible patients with MM and was successfully validated on an independent cohort of patients from the GEM-CLARIDEX trial. Most importantly, patients with 2%-20% CTCs had comparable dismal outcomes with primary PCL. Moreover, after revealing a low mean difference between flow cytometric and morphologic evaluation of CTCs, we showed that patients with 2%-5% CTCs have similar outcomes as those with 5%-20% CTCs. CONCLUSION: Our study uncovers that ≥ 2% CTCs is a biomarker of hidden primary PCL and supports the assessment of CTCs by flow cytometry during the diagnostic workup of MM.

16 March 2024 in Leukemia
Verified
Journal Article
Open access
PDF file
TJTomas Jelinek
Tomas Jelinek
DZD. Zihala
D. Zihala
TST. Sevcikova
T. Sevcikova
ASA. Anilkumar Sithara
A. Anilkumar Sithara
VKV. Kapustova
V. Kapustova
RHR. Hajek
R. Hajek
Extramedullary multiple myeloma (EMM) is an aggressive form of multiple myeloma (MM). This study represents the most comprehensive next-generation sequencing analysis of EMM tumors (N = 14) to date, uncovering key molecular features and describing the tumor microenvironment. We observed the co-occurrence of 1q21 gain/amplification and MAPK pathway mutations in 79% of EMM samples, suggesting that these are crucial mutational events in EMM development. We also demonstrated that patients with mutated KRAS and 1q21 gain/amplification at the time of diagnosis have a significantly higher risk of EMM development (HR = 2.4, p = 0.011) using data from a large CoMMpass dataset. We identified downregulation of CXCR4 and enhanced cell proliferation, along with reduced expression of therapeutic targets (CD38, SLAMF7, GPRC5D, FCRH5), potentially explaining diminished efficacy of immunotherapy. Conversely, we identified significantly upregulated EZH2 and CD70 as potential future therapeutic options. For the first time, we report on the tumor microenvironment of EMM, revealing CD8+ T cells and NK cells as predominant immune effector cells using single-cell sequencing. Finally, this is the first longitudinal study in EMM revealing the molecular changes from the time of diagnosis to EMM relapse.

10 July 2021 in Leukemia
Verified
Journal Article
Closed access
PDF file
TJTomas Jelinek
Tomas Jelinek
TSTereza Sevcikova
Tereza Sevcikova
DZDavid Zihala
David Zihala
TPTereza Popkova
Tereza Popkova
VKVeronika Kapustova
Veronika Kapustova
RHRoman Hajek
Roman Hajek

29 October 2018 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
TJTomas Jelinek
Tomas Jelinek
JMJana Mihalyova
Jana Mihalyova
MKMichal Kascak
Michal Kascak
JDJuraj Duras
Juraj Duras
TPTereza Popkova
Tereza Popkova
RHRoman Hajek
Roman Hajek

5 March 2026 in Blood
Verified
Journal Article
Open access
TJTomas Jelinek
Tomas Jelinek
DZDavid Zihala
David Zihala
AZAintzane Zabaleta
Aintzane Zabaleta
IKIoannis Kostopoulos
Ioannis Kostopoulos
Ondrej SoucekOndrej Soucek
Ondrej Soucek
RHRoman Hajek
Roman Hajek
Infections remain a challenge during treatment of patients with multiple myeloma (MM) with anti–B-cell maturation antigen (BCMA) and anti–G protein-coupled receptor class C group 5 member D (GPRC5D) bispecific antibodies (bsAbs). However, the mechanism underlying different rates and severity of infections induced by the 2 bsAbs remains poorly understood. Single-cell RNA sequencing of bone marrow (BM) aspirates of 11 patients with MM and 8 healthy donors revealed BCMA expression on mature B cells and, surprisingly, in small pre-B cells within B-cell precursors. GPRC5D expression was restricted to malignant and less to normal plasma cells (PCs). Next-generation flow cytometry immune profiling showed that anti-BCMA bsAbs severely depleted BM mature B cells, from 4.9% to 0% (P< .001), and normal PCs, from 0.17% to <0.0002% (P< .001), during treatment of 62 patients with relapsed MM. This was observed throughout therapy. Additional flow cytometry (n = 31) and single-cell RNA sequencing studies (n = 8) demonstrated that, in contrast to anti-GPRC5D, anti-BCMA bsAbs also depleted immature and small pre-B cells. The MIcγ1 mouse model was used as a negative control of BCMA expression in all stages of the B-cell lineage, confirming no depletion of any B-cell subset after anti-BCMA treatment. In conclusion, we show that although GPRC5D bsAbs selectively target PCs, anti-BCMA bsAbs target both PCs and B cells from the small pre-B stage onward. Our study provides mechanistic insight into the increased infection risk with anti-BCMA therapy and supports individualized bsAb strategies in MM. Moreover, dual targeting of B cells and PCs may have therapeutic potential in other B-cell malignancies or autoimmune diseases.

18 February 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
TPTereza Popkova
Tereza Popkova
RHRoman Hajek
Roman Hajek
TJTomas Jelinek
Tomas Jelinek